Citations

Clear

6273 citation(s) found for "To, Andrew".

Nuclear Magnetic Resonance-Based Glomerular Filtration Rate Estimation Is More Closely Associated with Serum Vancomycin Target Trough Achievement vs. Serum Creatinine-Based Equations
Barreto, Jason N. , Santamaría, Amauri Schwäble , Grassi, M , Robertson, Andrew, Meeusen, Jeff W., Schiffer, Eric, Frazee, Erin N. , Schwäble Santamaria, Amauri , Grassi, Marcello, Lieske, John C. , Meeusen, Jeffrey W.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024cxwpvjcv Get It

MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
Appel, Gerald B., Prot, Sylvie, Berisha, Eriola, Khatri, Leena, Parsons, T. M. C., Spinks, E. Ann, Boston, Heather, Riboulet, William, Han, Xiaoyan , Fervenza, Fernando C. , Gesualdo, Loreto , Kirsztajn, Gianna Mastroianni , Hou, Fan Fan , Berisha, Eriola, Chen, Debbie , Bomback, Andrew S.

Mayo Clinic

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024bg7j9nj3 Get It

Clinical outcomes of atrial high-rate episodes: an updated meta-analysis
Mangat, M M Manvir, Palicherla, Anirudh , Kashou, Anthony H. , Dufani, Jalal, Anavekar, Nandan S., Aboeata, Ahmed, Ahmed, H, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.435 Get It

Abstract Background Atrial high-rate episodes (AHRE) are commonly detected in individuals with cardiac implantable electronic devices. Outcomes of atrial high-rate episodes remain unclear in those without a prior history of atrial fibrillation. Purpose This study aims to evaluate clinical outcomes of atrial high-rate episodes in patients who have no prior history of atrial fibrillation. Methods PubMed, EMBASE, and Cochrane databases were searched through February 2024 for studies evaluating clinical outcomes in individuals with cardiac implantable electronic devices who experienced atrial high-rate episodes, compared to those who did not. Individuals who had a prior history of atrial fibrillation were excluded. Outcomes assessed were clinical atrial fibrillation, thromboembolic events, and all-cause mortality. A fixed-effects model was used to calculate risk ratios (RRs) with 95% confidence intervals (CI). A subgroup analysis of thromboembolic events was conducted based on the duration of atrial high-rate episodes. Results A total of 9 studies met inclusion criteria with a combined enrollment of 7440 patients. Compared to those who did not experience atrial high-rate episodes, those who did had significantly increased risks of clinical atrial fibrillation (RR 3.33; 95% CI 1.99 - 5.57; P < 0.0001) and thromboembolic events (RR 2.21; 95% CI 1.72 -2.85; P < 0.0001). The risk of all-cause mortality was similar between both groups (RR 1.19; 95% CI 0.95 – 1.49; P = 0.13). Subgroup analysis revealed an increased risk of thromboembolic events among atrial high-rate episodes ≥ 24 hours (RR 12.34; 95% CI 2.70 – 56.36) while atrial high-rate episodes lasting < 24 hours were insignificantly associated with thromboembolic events (RR 0.83; 95% CI 0.12 – 5.58). Conclusions Our study indicates a heightened risk of clinical atrial fibrillation and thromboembolic events among patients with atrial high-rate episodes, with no observed increase in mortality risk. Furthermore, our findings suggest that the duration of atrial high-rate episodes influences the risk of thromboembolism. Further studies are warranted to confirm our findings.
Cardiopulmonary exercise testing predicts risk of progressive heart failure and long term mortality in ambulatory patients awaiting isolated heart transplant
Daly, Richard C. , Villavicencio, Mauricio A. , Spencer, Philip J. , Stephens, Elizabeth H. , Todd, Andrew C. , Briggs, Carol, Aguilar, Maria I. , Kushwaha, Sudhir S. , Allison, Thomas, Afoke, Jonathan , Dearani, Joseph A. , Tang, Paul C. , Todd, A, Briggs, C, Patel, K

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.916 Get It

Abstract Introduction Cardiopulmonary exercise testing (CPET) parameters such as peak VO2 ≤ 14ml/kg/min, percentage predicted peak VO2 (ppVO2) ≤ 50% and ventilation equivalent of carbon dioxide (Ve/VCO2) >35 l/min/l/min are recommended thresholds to list for isolated heart transplant. There is minimal data on clinical events after listing to guide clinical management or priority in organ allocation. Purpose To assess the effect of peak VO2, ppVO2, Ve/VCO2 on clinical events after listing for isolated heart transplant. Methods In a single centre retrospective study, we identified patients who were status 6 or status 2 prior to 2018 at time of listing for isolated heart transplant between 2007 and 2021. Clinical data were collected by chart review. Primary outcome of progressive heart failure was defined as death or upgrade in transplant priority status (new inotropes or mechanical circulatory support). Comparison was made between peak VO2 strata (> 14 vs ≤ 14 ml/kg/min), ppVO2 strata (> 50% vs 40-50% vs <40%) and Ve/VCO2 strata (<35 vs >35 l/min/l/min). Secondary outcome was time dependent survival after listing for heart transplant. Results We identified 141 patients of which 133 underwent CPET and follow up was available for 130 who were included in the analysis. Median age was 53 years (interquartile range 41-59 years), 29.1% of patients were female. Median peak VO2 was 14.0 ml/kg/min (11.2-15.7), ppVO2 was 44% (36-52), Ve/VCO2 slope was 34.0 (31.0-37.0) and RER was 1.1 (1.1-1.2). 87 patients had progressive heart failure consisting of 34 deaths and 83 patients having upgrade in priority status. There was a significant difference in risk of progressive heart failure comparing peak VO2 strata (Figure 1) (freedom from event at one year 71.4% with peak VO2 > 14 vs 46.5% with peak VO2 ≤ 14, p=0.00061) and ppVO2 strata (Figure 2) (freedom from event at one year 75.0% with ppVO2 >50% vs 61.2% with ppVO2 40-50% vs 42.6% with ppVO2 <40%, p=0.0015). There was no significant difference with Ve/VCO2 strata (freedom from event at one year 59.8% with Ve/VCO2 <34 vs 54.9% with Ve/VCO2 >34, p=0.52). There were 34 deaths before transplant and 23 deaths after transplant. 87 patients underwent transplant. In a time dependent survival analysis, age, gender and ppVO2<50% (HR 1.65 (0.87-3.12)) were not significant predictors of mortality. Both early transplant (defined as < 1 year after listing, HR 0.14 (0.06-0.34) and late transplant (defined as > 1 year after listing, HR 0.16 (0.08-0.32)) were significant predictors of lower mortality whilst Ve/VCO2>35 (HR 2.09 (1.19-3.68)) was a significant predictor of higher mortality. Conclusions Peak VO2 and ppVO2 stratify risk of progressive heart failure in ambulatory patients awaiting isolated heart transplant. However, Ve/VCO2 is a predictor of significantly higher mortality. These findings should affect clinical management and transplant priority status; and influence revision of future guidelines.Freedom from event by peak VO2 strataFreedom from event by ppVO2 strata
The role of anticoagulation in atrial high-rate episodes: a meta-analysis
Mangat, M M Manvir, Palicherla, Anirudh , Anavekar, Nandan S., Aboeata, Ahmed, Ahmed, H, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.3334 Get It

Abstract Background The role of anticoagulation in patients with atrial high-rate episodes (AHRE), who have no prior history of atrial fibrillation or atrial flutter, is being extensively studied. Purpose Given the increased thrombo-embolic risk in patients who have atrial high-rate episodes, our aim was to evaluate whether anticoagulation leads to enhanced clinical outcomes compared to no anticoagulation (1). Methods We searched PubMed, EMBASE, and the Cochrane Library, through February 2024, for studies evaluating outcomes in patients with atrial high-rate episodes managed with oral anticoagulation (OAC) compared to those not managed with oral anticoagulation. Outcomes assessed were ischemic stroke, thromboembolic events, major bleeding, and all-cause mortality. A fixed-effects model was used to calculate pooled risk risk ratios (RR) and their 95% confidence intervals (CI). Results A total of 4 studies comprising 6788 patients were included. Anticoagulation was associated with a significant reduction in the risks of ischemic stroke (RR 0.66; 95% CI 0.49 - 0.90; P = 0.0084) and thromboembolic events (RR 0.70; 95% CI 0.55 - 0.89; P = 0.0037). Compared to atrial high-rate episodes not managed with anticoagulation, there was a significantly increased risk of major bleeding with anticoagulation (RR 1.57; 95% CI 1.23 - 2.00; P = 0.0002), while the risk of all-cause mortality was similar (RR 1.07; 95% CI 0.95 - 1.21; P = 0.2437). Conclusion Our study suggests that anticoagulation in patients with atrial high-rate episodes decreases the risks of ischemic stroke and thromboembolic events, while increasing the risk of major bleeding, compared patients not managed with anticoagulation. Our study does not show a mortality benefit with the use of anticoagulation in patients with atrial high-rate episodes. Further studies are needed to confirm the safety and efficacy of anticoagulation in atrial high-rate episodes.Forest Plots of Outcomes Assessed
Worse ischemic symptoms and cardiac function in women with suspected ischemia with no obstructive coronary artery disease and adverse pregnancy outcomes history
Oneglia, Andrew P. , Tapp, D R, Maughan, Jenna , Wei, Jiajun , Tamarappoo, Balaji , Nelso, M N, Quesada, Odayme , Lauzon, Michel Louis , Shufelt, Chrisandra , Pepine, Carl J. , Merz, C. Noel Bairey

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.3233 Get It

Abstract Background Adverse pregnancy outcomes (APO) are associated with increased maternal risk of cardiovascular disease (CVD) and mortality. Ischemia with no obstructive coronary artery disease (INOCA) is predominant in women, however the association of APO history with INOCA is poorly understood. Purpose To compare clinical characteristics, symptoms, cardiac structure and function and coronary microvascular dysfunction in women suspected to have INOCA with or without a history of APO. Methods Women’s Ischemia Syndrome Evaluation (WISE) CVD (NCT00832702) and WISE pre-HFpEF (NCT02582021) prospective cohorts of women with suspected INOCA were merged and utilized to determine among women with at least 1 prior pregnancy whether a history of APO was associated with ischemic symptoms, and to characterize CMRI measured left ventricle (LV) structure and function, myocardial deformation (systolic and diastolic strain) and coronary microvascular dysfunction on invasive coronary functional testing (CFT). Self-reported APO was defined as hypertensive disorder of pregnancy (HDP), gestational diabetes, preterm birth (<37-week gestation), low birth weight (<5lbs). Results In a cohort of 469 women with suspected INOCA, (mean average age 55 [SD 10.2] years) and at least 1 prior pregnancy, 138 (29%) had history of at least 1 APO. Among women with history of APO, 78 reported HDP, 50 gestational diabetes, 27 pre-term birth, 8 low birth weight. Women with a history of APO were younger, had higher rates of hypertension and diabetes, higher BMI and lower SAQ and DASI scores compared to those with no history of APO (Table). LV ejection fraction (EF) was lower and early diastolic strain rate/LVEDP was higher in women with APO history compared to those without APO history. Conclusion(s) In cohort of women with INOCA, history of APO was highly prevalent. Despite younger age, women with history of APO had higher rates of CVD risk factors, worse ischemic symptoms and functional capacity, lower EF, and higher filling pressures. Our findings suggest a potential for APO history to better identify women with worse prognosis that warrants further investigation and aggressive management.
Racial, ethnic, and sex disparities in the utilization and outcomes of tricuspid valve surgery
Alkhouli, Mohammad, Ismayl, Mahmoud , Ahmed, H, Goldsweig, Andrew M. , Guerrero, Mayra

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2496 Get It

Abstract Background Data on racial/ethnic and sex disparities in the utilization and outcomes of tricuspid valve surgery (TVS) in the United States are scarce. Purpose We aimed to evaluate the impact of race/ethnicity and sex on the utilization and outcomes of TVS. Methods We analyzed the National Inpatient Sample database from 2016 to 2020 to identify hospitalizations for tricuspid valve surgery. Racial/ethnic and sex disparities in tricuspid valve surgery outcomes were determined using logistic regression models. Results Between 2016 and 2020, 19,395 hospitalizations for tricuspid valve surgery were identified. The utilization rates (defined as the number of tricuspid valve surgery performed per 100,000 US hospitalizations) were lower in Black and Hispanic patients compared with White patients for surgical tricuspid valve repair (331 versus 493 versus 634, p<0.01) and surgical tricuspid valve replacement (312 versus 601 versus 728, p<0.01). Similarly, the utilization rates were lower for women compared with men for surgical tricuspid valve repair (1,021 versus 1,364, p<0.01) and surgical tricuspid valve replacement (930 versus 1,316, p<0.01). Compared to White men undergoing tricuspid valve surgery, all women had lower odds of acute kidney injury (aOR 0.65, 95% CI 0.55-0.78) and higher odds of blood transfusion (aOR 1.30, 95% CI 1.07-1.59), and Black men had higher odds of blood transfusion (aOR 1.59, 95% CI 1.08-2.35). In-hospital mortality and other surgical complications were similar between all groups (all p>0.05). Conclusions Significant racial/ethnic and sex disparities exist in the utilization of tricuspid valve surgery in the United States. Further studies are needed to understand the reasons for these disparities and to identify effective strategies for their mitigation.
Unlocking the future: machine learning models for predicting in-hospital mortality after transcatheter aortic valve replacement: a single-arm meta-analysis
Mangat, M M Manvir, Palicherla, Anirudh , Ellauzi, Rama , Kalathil, Ruth Ann Mathew, Pusapati, Suma , Dufani, Jalal, Aboeata, Ahmed, Anavekar, Nandan S., Ahmed, H, Ismayl, Mahmoud , Goldsweig, Andrew M.

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2455 Get It

Abstract Background Transcatheter aortic valve replacement (TAVR) continues to be increasingly performed. While machine learning has demonstrated utility in predicting adverse outcomes in various cardiovascular procedures, its effectiveness in predicting in-hospital mortality in TAVR remains uncertain. Purpose We aimed to examine the accuracy of machine learning in predicting in-hospital mortality in TAVR. Methods We searched PubMed and Cochrane databases up to February 2024 for observational studies assessing the diagnostic accuracy of machine learning for predicting in-hospital mortality in TAVR. Extracted data included study characteristics, patient demographics, type of predictive model used, and area under the receiver operating characteristic curves (AUC). Predictive accuracy was assessed by pooling AUC of machine-learning models across studies. AUC values ranging from 0.80 to 0.90, 0.70 to 0.80, 0.60 to 0.70, and 0.50 to 0.60 corresponded to excellent, good, fair, and poor discrimination ability, respectively (1). We used a random effects model to estimate the overall effect size with a 95% confidence interval (CI). Heterogeneity was evaluated with the I2 test.We conducted subgroup analyses based on the type of machine-learning model utilized to assess for any potential differences in predictive accuracy. Results A total of three studies were identified, comprising a study population of 70,714 patients. Across studies, eight machine learning models were utilized, consisting of three artificial neural network models, one logistic regression model, one naive Bayes model, two random forest models, and one support vector machine model. Pooled AUC showed excellent accuracy of machine learning in predicting in-hospital mortality in TAVR (0.92; 95% CI 0.90 - 0.95). Subgroup analyses revealed similar yet excellent accuracy across all types of machine learning models utilized: artificial neural network (0.92; 95% CI 0.86-0.99), logistic regression (0.92; 95% CI 0.89-0.95), naive Bayes (0.90; 95% CI 0.88-0.92), random forest (0.94; 95% CI 0.87-1.00), and support vector machine (0.94; 95% CI 0.91-0.96). Conclusion Our study suggests that utilizing machine learning can accurately predict in-hospital mortality in TAVR. Operators of TAVR procedures may benefit from incorporating machine learning prediction models in their clinical practice. Further exploration of machine learning on outcomes in TAVR is needed to verify our findings.
Serial changes in left and right ventricular global longitudinal strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
Desai, Milind Y. , Wolski, Kathy , Owens, Amanda, Geske, Jeffrey B. , Saberi, Sima, Cremer, Paul , Tower‐Rader, Albree, Lakdawala, Neal K. , Fermin, Damian , Naidu, Suveeksha, Lampl, Kathy, Sehnert, Amy J. , Fermin, David , Geske, Jeffrey B , Cremer, Paul C , Fermin, David , Okushi, Yuichiro , Popovic, Zoran B , Owens, A, Wang, Andrew

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2013 Get It

Abstract Background In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM phase 3 randomized, double-blind, placebo-controlled clinical trial demonstrated that mavacamten, reduces the need for septal reduction therapy with sustained improvement in left ventricular outflow tract gradients and symptoms. As a cardiac myosin inhibitor, mavacamten’s mechanism of action reduces myocardial hypercontractility. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function and can complement left ventricular ejection fraction (LVEF). Objective We sought to assess serial changes in LV and right ventricular (RV)-GLS in patients enrolled in the VALOR-HCM study. Methods VALOR-HCM included 112 symptomatic obstructive HCM patients (mean 60 years, 51% male, LVEF 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo crossed over to mavacamten (n=52) from week 16-56 (40-week exposure). LV and RV-GLS assessment was performed according to the current American and European guideline recommendations using a vendor-neutral post processing software. Non-foreshortened apical (4, 3 and 2-chamber) views were used to obtain peak value of LV-GLS. For RV-GLS, RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. Results Serial changes in LVEF, average LV-GLS, and RV-GLS (4-chamber and free wall) from baseline to week 56 are shown in the Figure. Despite preserved LVEF at baseline, average baseline LV-GLS was abnormal. There were significant and continued improvements in LV-GLS in the total group from baseline to week 56. 12 patients had transient reduction in LVEF (<50%) requiring temporary drug interruption (permanent discontinuation in 3). The LV-GLS in this subgroup was worse at baseline compared to the total study population, with no significant worsening from baseline through week 56. In the overall population, excluding these 12 patients, LV-GLS demonstrated an improvement sustained through week 56. Both free wall and 4-chamber RV-GLS were abnormal at baseline and remained unchanged from baseline to week 56. Conclusions In the VALOR-HCM trial, despite hypercontractile LVEF at baseline, average baseline LV-GLS was worse than normal reference values. Treatment with mavacamten resulted in an improvement in LV-GLS from baseline through Week 56 (with no significant worsening of LV-GLS in the subgroup who experienced any reduction in LVEF <50%), suggesting a favorable long-term impact on regional LV systolic function due to the reduction of cardiac hypercontractility. Additionally, there was no significant detrimental impact on RV systolic function on serial GLS assessment.Serial changes in LV and RV GLS in VALOR
A cohort study examining predictors of stroke and bleeding among people with congenital heart disease and atrial fibrillation
O’Shea, Molly , Ravi, Sandhya, Ligten, Matthew Van, Ibrahim, Amna , Wang, Wen‐Yen, Alozie, Nneoma, Girardo, Marlene , Egbe, Alexander C. , Karikalan, Suganya Arunachalam , Baqal, Omar J , Bacon, Andrew K. , Smyth, P, Marshall, C, Egbe, Alexander C. , Majdalany, David S , Masry, Hicham El

Mayo Clinic

European Heart Journal | October 28, 2024 | Volume: 45 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehae666.2150 Get It

Abstract Background Congenital Heart Disease (CHD) is associated with development of atrial fibrillation (AF) at an early age. With increased survival of this cohort into adulthood, the prevalence of concurrent CHD and AF is expected to increase over the next several decades. Little is known about the utility of clinical risk factors or prediction models in determining bleeding or stroke rates in adults with CHD and AF. Purpose This study aims to measure the performance of the CHADSVASC and HASBLED scores in a cohort of people with CHD. The association between traditional stroke and bleeding risk factors, as well as CHD-specific factors, will be quantified. Methods Patients age 18 or older attending one of three centers in the USA were included in this study if they had a history of AF on ECG, holter monitor or device interrogation, in addition to a diagnosis of Tetralogy of Fallot (TOF), Double Outlet Right Ventricle (DORV), or Pulmonary Atresia with Intact Ventricular Septum (PA-IVS). Outcomes were major bleeding event, and stroke rate. Analysis was conducted using cox univariable regression controlling for current age. Receiver operator curve and c-statistics were produced for the CHADSVASC and HASBLED scores respectively. Results 326 people were included in this study, of whom 161 (49.5%) had TOF secondary to Pulmonic Stenosis, 126 (38.8%) had TOF secondary to Pulmonary Atresia, 25 (7.7%) had DORV, and 155 (47.7%) had PA-IVS. 227 people used warfarin (79.4%), 28 (9.8%) used apixaban, 9 (3.1%) used Rivaroxaban, 3 (1%) used Edoxaban, and 5 (1.7%) used Enoxaparin for a period of at least 30 days during the study. 13 (4.5%) people didn’t receive anticoagulation during the study. 26 people had a stroke (8.8%) while 85 people (28.6%) had a major bleeding event. Only the CHADSVASC score was significantly associated with stroke rates (HR 2.103, 95% CI 1.555 to 2.844, p<0.001). Clinical variables, such as subtype of CHD, prior conduit placement or unifocalization were not associated with stroke or major bleeding events. C-statistic for the CHADSVASC score in predicting stroke events was 0.755 (Figure 1). C-statistic for the HASBLED score in predicting major bleeding was 0.442 (Figure 2). Conclusions Among people with CHD and AF, the CHADSVASC score can robustly predict stroke events. Other clinical variables are less valuable in predicting either bleeding or strokes. The HASBLED score likely doesn’t have a role in predicting major bleeding episodes in this cohort.